Orexin agonists as novel obesity therapeutics

食欲素激动剂作为新型肥胖疗法

• 批准号: 10369478
• 负责人: CATHERINE M KOTZ
• 金额: --
• 依托单位: MINNEAPOLIS VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10369478
• 关键词: Address; Adult; Affect; Affinity; Age; Agonist; Anti-Obesity Agents; Automobile Driving; Behavior; Behavioral; Biological Availability; Blood - brain barrier anatomy; Body Weight; Body Weight decreased; Brain; Calories; Caring; Chronic Disease; Cognition; Data; Desire for food; Development; Diet; Eating; Effectiveness; Energy Metabolism; Environment; Evaluation; Exercise; Exposure to; Feeding behaviors; Future; General Population; Goals; Health; Health Care Costs; Healthcare Systems; High Fat Diet; Home; Homeostasis; Human; Hypothalamic structure; Indirect Calorimetry; Individual; Lateral; Measures; Medical; Metabolic; Metabolic Diseases; Methods; Modeling; Moderate Exercise; Molecular Weight; Morbidity - disease rate; Movement; Mus; Narcolepsy; Neurodegenerative Disorders; Neurons; Neuropeptides; Obese Mice; Obesity; Outcome; Overweight; Pattern; Peptide Hydrolases; Peptides; Peripheral; Pharmaceutical Preparations; Pharmacotherapy; Physical Exercise; Physical activity; Physiological; Population; Prevention; Property; Quality of life; Radio; Receptor Activation; Research; Rodent; Sleep; Sleep Disorders; Sleep Wake Cycle; Sleep disturbances; Structure; Subconscious; System; Telemetry; Testing; Therapeutic; Thermogenesis; Treatment outcome; Vertebral column; Veterans; Veterans Health Administration; Weight Gain; base; blood-brain barrier permeabilization; comorbidity; diet-induced obesity; effective therapy; efficacy testing; exercise program; good diet; healthspan; hypocretin; improved; in vivo; interest; military veteran; novel; obese person; obesity development; obesity prevention; obesity treatment; obesogenic; orexin A; pre-clinical; prevent; receptor; reduced food intake; research and development; scale up; side effect; small molecule; success; therapeutic target; tool; total energy expenditure; weight maintenance; wireless

Overweight and obesity are common among Veterans served by the Veterans Health Administration (VHA). Obesity and the chronic diseases associated with obesity place a tremendous burden on our healthcare system and reduce quality of life for the general population as well as for Veterans. As our Veteran population ages over the next decades, this burden will only increase. In addition to few effective pharmacotherapies for obesity prevention, there are no effective therapies for long-term weight maintenance after weight loss in obese subjects. Therapeutically targeting fundamental mechanisms that drive energy expenditure has a larger dividend in terms of improving the health of the overweight Veteran population than would treating individual co-morbidities associated with obesity. One of the possible mechanisms for the development of obesity is decreased availability of the hypothalamic neuropeptide orexin. The orexin neuropeptide, produced in the lateral hypothalamus, are key regulators of physiological functions, including energy homeostasis, sleep/wake stabilization and cognition. A defective orexin system results in weight gain despite reduced food intake, and complete absence of orexin neurons results in the sleep disorder narcolepsy, which is also characterized by weight gain, despite reduced food intake. We and others have consistently demonstrated that orexin enhances physical activity and energy expenditure, and improves sleep/wake patterns. Despite this demonstration that the orexin system can be targeted for weight loss, it’s not feasible to peripherally administer the orexin peptide itself due to its lack of blood- brain barrier permeability. Therefore, to achieve obesity therapies based on orexin, the development and testing of small molecular weight orexin agonists is needed. The overarching hypothesis of this proposal is that small molecular weight agonists for orexin will prevent and reverse diet-induced obesity, through increasing energy expenditure and improving sleep/wake patterns. The goals are to systematically test the efficacy of two small molecule orexin agonists in preventing and reversing high-fat diet-induced obesity by enhancing energy expenditure and improving sleep/wake behavior. To this end, we will expose mice to high-fat diet and use indirect calorimetry in conjunction with wireless radio-telemetric sleep/wake behavioral analyses, to determine if activation of orexin receptors using peripheral novel small molecule orexin agonists prevents and/or reverses obesity, and improves behavioral sleep/wake patterns. The immediate goal is to generate sufficient preclinical data to support use of small molecular-weight orexin agonists to prevent adverse body weight outcomes associated with exposure to obesogenic environments. The long-term goal is to enable research and development of orexin agonists as therapies for obesity and associated comorbidities commonly observed in the Veteran population.

超重和肥胖在退伍军人健康管理局 (VHA) 服务的退伍军人中很常见。 肥胖和与肥胖相关的慢性疾病给我们的医疗保健系统带来了巨大的负担 随着我们的退伍军人人口老龄化，普通民众和退伍军人的生活质量下降。 在接下来的几十年里，除了少数有效的肥胖药物疗法之外，这种负担只会增加。 预防方面，对于肥胖受试者减肥后长期维持体重尚无有效疗法。 针对驱动能量消耗的基本机制的治疗具有更大的红利 与治疗个人合并症相比，更能改善超重退伍军人的健康 与肥胖相关的可能机制之一是可用性降低。 下丘脑神经肽食欲素 食欲素神经肽在下丘脑外侧产生。 生理功能的关键调节因子，包括能量稳态、睡眠/觉醒稳定和认知。 尽管食物摄入量减少且食欲素完全缺失，但食欲素系统有缺陷仍会导致体重增加 神经元会导致睡眠障碍发作性睡病，其特征还包括体重增加，尽管体重增加 我们和其他人一致证明，食欲素可以增强身体活动和能量。 尽管有证据表明食欲素系统可以改善睡眠/觉醒模式。 以减肥为目标，由于缺乏血液，在外周施用食欲素肽本身是不可行的。 因此，为了实现基于食欲素的肥胖疗法，进行了开发和测试。 需要小分子量食欲素激动剂。 该提案的总体假设是小分子量食欲素激动剂将阻止 通过增加能量消耗和改善睡眠/觉醒模式来逆转饮食引起的肥胖。 目标是系统地测试两种小分子食欲素激动剂在预防和逆转 通过增加能量消耗和改善睡眠/觉醒行为来减少高脂肪饮食引起的肥胖。 我们将让小鼠接受高脂肪饮食，并结合无线无线电遥测技术使用间接量热法 睡眠/清醒行为分析，以确定是否使用外周新型小分子激活食欲素受体 分子食欲素激动剂可预防和/或逆转肥胖，并改善行为睡眠/觉醒模式。 近期目标是产生足够的临床前数据来支持小分子量食欲素激动剂的使用 防止与暴露于致肥胖环境相关的不良体重结果。 目标是使食欲素激动剂的研究和开发成为肥胖及相关疾病的治疗方法 退伍军人中常见的合并症。